Abstract
The package insert of 4-factor prothrombin complex concentrate (4F-PCC) contains specific dosing recommendations stating to determine the patients dose based on their INR and weight, capping the weight at 100 kg. However, the mean body mass index (BMI) in the 4F-PCC U.S. approval study was 27 kg/m2, and there is a lack of literature identifying the ideal dosing strategy in obesity. We conducted a retrospective analysis of obese patients (BMI ≥ 30 kg/m2) who received 4F-PCC for warfarin associated emergent bleeding reversal. Treatment groups were those that received 4F-PCC on adjusted body weight (AdjBW) and those on actual body weight (ActBW). The primary outcome was the percent of patients achieving coagulopathy reversal, defined as a post-treatment INR < 1.4 for neurologic indications and < 1.5 for all others. A total of 78 obese patients were included (28 AdjBW and 50 ActBW). Baseline INR (3.1 vs. 2.8; p = 0.052) and BMI (33.6 vs. 33.6 kg/m2) were similar between groups. Achievement of goal INR was significantly lower in the AdjBW group (36% vs. 68%; p = 0.006). A majority of patients had intracranial hemorrhage (32% vs. 54%; p = 0.06), and the median dose of 4F-PCC was lower in the AdjBW group (2120 vs. 2500 units; p = 0.02). Dosing 4F-PCC using adjusted body weight in obese patients resulted in a significantly lower rate of coagulopathy reversal. ActBW should be used to dose 4F-PCC in obese patients when the 100 kg dose cap is utilized per the package insert recommendations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ogden CLCM, Fryar CD, Flegal KM (2015) Prevalence of obesity among adults and youth: United States, 2011–2014. National Center for Health Statistics Data Brief Centers for Disease Control and Prevention, Washington, DC
Lonardo NW, Lonardo LF, Mone MC, Simons HJ, Barton RG (2016) Should the dose of recombinant activated factor VII be adjusted for morbidly obese patients? Balancing risk of bleeding with thrombosis. J Hematol 5:60–66. https://doi.org/10.14740/jh256w
Kcentra® [package insert] (2013) CSL Behring, KoP, PA
Graham A, Jaworski K (2014) Pharmacokinetic analysis of anti-hemophilic factor in the obese patient. Haemophilia 20:226–229. https://doi.org/10.1111/hae.12300
Adcock D, Bethel MA, Macy PA (2006) Coagulation handbook. Esoterix, Inc. https://www.esoterix.com/sites/esoterix/files/imce/uploads/L3692.pdf. Accessed 21 Mar 2018
Jones GM, Erdman MJ, Smetana KS, Mohrien KM, Vandigo JE, Elijovich L (2016) 3-Factor versus 4-factor prothrombin complex concentrate for warfarin reversal in severe bleeding: a multicenter, retrospective, propensity-matched pilot study. J Thromb Thrombolysis 42:19–26. https://doi.org/10.1007/s11239-015-1330-3
Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, del Zoppo GJ, Kumar MA, Peerschke EI, Stiefel MF, Teitelbaum JS, Wartenberg KE, Zerfoss CL (2016) Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 24:6–46. https://doi.org/10.1007/s12028-015-0222-x
Radaelli F, Dentali F, Repici A, Amato A, Paggi S, Rondonotti E, Dumonceau JM (2015) Management of anticoagulation in patients with acute gastrointestinal bleeding. Dig Liver Dis 47:621–627. https://doi.org/10.1016/j.dld.2015.03.029
Lemmens HJ, Bernstein DP, Brodsky JB (2006) Estimating blood volume in obese and morbidly obese patients. Obes Surg 16:773–776. https://doi.org/10.1381/096089206777346673
Devine B (1974) Gentamicin therapy. DICP Ann Pharmacother 8:650–655
Cheymol G (1993) Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 25:103–114. https://doi.org/10.2165/00003088-199325020-00003
Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN (2013) Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 128:1234–1243. https://doi.org/10.1161/CIRCULATIONAHA.113.002283
Strate LL, Gralnek IM (2016) ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol 111:755. https://doi.org/10.1038/ajg.2016.155
Shingina A, Barkun AN, Razzaghi A, Martel M, Bardou M, Gralnek I, Investigators R (2011) Systematic review: the presenting international normalised ratio (INR) as a predictor of outcome in patients with upper nonvariceal gastrointestinal bleeding. Aliment Pharmacol Ther 33:1010–1018. https://doi.org/10.1111/j.1365-2036.2011.04618.x
Jairath V, Kahan BC, Stanworth SJ, Logan RF, Hearnshaw SA, Travis SP, Palmer KR, Murphy MF (2013) Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. Transfusion 53:1069–1076. https://doi.org/10.1111/j.1537-2995.2012.03849.x
Tran HA, Chunilal SD, Tran H (2014) An update of consensus guidelines for warfarin reversal. Med J Aust 200:82
Author information
Authors and Affiliations
Contributions
Study conception and design: KSS, RZ, CCM, MJE, ETVM, GMJ. Acquisition of data: KSS, RZ, CCM, MJE, GMJ. Analysis and interpretation of data: KSS, RZ, CCM, MJE, ETVM, GMJ. Critical revision of manuscript: KSS, RZ, CCM, MJE, ETVM, GMJ.
Corresponding author
Ethics declarations
Conflict of interest
All authors of this study have no direct or indirect conflicts of interest to disclose.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Smetana, K.S., Ziemba, R., May, C.C. et al. Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding. J Thromb Thrombolysis 47, 369–374 (2019). https://doi.org/10.1007/s11239-018-1771-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-018-1771-6